/PRNewswire/ CyGenica Limited, a dynamic biotech startup announced today a significant achievement in the battle against Glioblastoma Multiforme (GBM), a.
Share this article
Share this article
PUNE, India and CORK, Ireland, June 10, 2021 /PRNewswire/ CyGenica has announced that it has raised USD $1.4 million in a seed fund investment round, led by global venture capital investor SOSV. The funding round will accelerate validation of CyGenica s proprietary technology, which enables safe, targeted and affordable intercellular drug delivery.
The current investment seed round was led by venture capital investor SOSV. Other investors participating in the round included the VOYAGER Health-Tech fund, David Rowan, founder of Voyagers.io and angel investors Sharaf Yamani and Sami Mikati.
CyGenica intends to utilize the investment to accelerate the development of its disruptive drug delivery technology, establish as a key partner of biopharmaceutical companies in the advancement of cutting-edge therapeutics for cancer and rare diseases to improve patient s health and quality of life.